Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo Expands Puerto Rico Sales Force

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Daiichi Sankyo completed lining up a Puerto Rico sales force and will now accelerate sales expansion of its core lines of products in Puerto Rico, offering the same products as those being sold in the United States by taking advantage of its U.S. commonwealth status, enabling the company to sell products approved by the U.S. FDA, Daiichi Sankyo spokesperson Maho Tanabe told PharmAsia News Jan. 13

You may also be interested in...



Daiichi Sankyo Optimistically Ramping Up For Prasugrel Launch

Daiichi Sankyo CEO Takashi Shoda acknowledged during the company's third quarter results call that the delay in U.S. FDA approval of Effient (prasugrel), a novel platelet inhibitor that the company filed jointly with Eli Lilly in December 2007, has negatively affected the company net sales forecast

Daiichi Sankyo Optimistically Ramping Up For Prasugrel Launch

Daiichi Sankyo CEO Takashi Shoda acknowledged during the company's third quarter results call that the delay in U.S. FDA approval of Effient (prasugrel), a novel platelet inhibitor that the company filed jointly with Eli Lilly in December 2007, has negatively affected the company net sales forecast

U.S. FDA Confirms Daiichi/Lilly Prasugrel Advisory Committee Review; What Will Panel Membership Entail?

As preparations get underway for the Feb. 3 advisory committee review of Lilly and Daiichi Sankyo's platelet inhibitor prasugrel, one indicator of the drug's prospects will be the individuals who are asked by U.S. FDA to serve on the expert panel

Related Content

UsernamePublicRestriction

Register

SC069801

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel